Important Correction from Kintara Therapeutics
Kintara Therapeutics, Inc. (NASDAQ: KTRA), a biopharmaceutical company concentrating on fresh cancer therapies, has recently announced a critical correction pertaining to earlier communications regarding its planned merger with TuHURA Biosciences, Inc. This announcement clarifies the details surrounding a reverse stock split that was authorized by Kintara's Board of Directors.
Understanding the Reverse Stock Split
The reverse stock split will be executed at a ratio of 1-for-35, which means that for every thirty-five shares of common stock that predate the split, stockholders will receive one share post-split. The adjustments will be initiated on the Nasdaq Capital Market shortly after the Merger with TuHURA closes. This is a significant restructuring in Kintara’s share approach and aims to optimize trading liquidity.
Overview of the Merger with TuHURA
This merger is an important transitional step for Kintara, enabling its common stock to be rebranded as TuHURA Biosciences, Inc., with a new ticker symbol 'HURA'. The merger includes an adjustment in the CUSIP number for the common stock post-split, which reflects the new stock structure.
Impact on Shareholders
Shareholders will see their shares consolidated; thus, the approximate reduction of Kintara's outstanding shares from roughly 55.6 million to about 1.6 million will occur. The split maintains the par value per share at $0.001. Notably, the ratio allows for a smooth transition for shareholders, ensuring all stockholders uniformly experience the effects of the reverse split.
Handling of Fractional Shares
In terms of fractional shares, no such shares will be issued as a result of the reverse stock split. Instead, Kintara will offer shareholders additional shares needed to round up any resulting fractions to the nearest whole share. This ensures equitable treatment for all shareholders post-split.
Future of Kintara Therapeutics
Post-merger, Kintara’s combined outstanding equity is projected to be around 42 million shares. The company continues to move forward with a strong focus on delving deeper into promising cancer therapies, leveraging partnerships for enhanced growth and innovation. Equinity Trust Company, LLC is managing the transition and acting as the exchange agent for this split.
Innovation at TuHURA Biosciences
TuHURA Biosciences is trailblazing its path in the immuno-oncology space, fully engaged in developing groundbreaking strategies to combat resistance faced by cancer therapies. Their leading personalized cancer vaccine candidate is poised for extensive clinical evaluation.
About Kintara Therapeutics
Kintara Therapeutics is dedicated to advancing the field of oncology through novel treatment modalities. Its flagship program, REM-001 Therapy, positions the company at the forefront of targeted cancer therapies. Kintara is committed to addressing significant gaps in cancer treatment, focusing on unmet medical needs with a strong emphasis on patient well-being and therapeutic effectiveness.
Frequently Asked Questions
What is the purpose of Kintara's reverse stock split?
The reverse stock split aims to enhance the company's stock price and improve trading liquidity, aligning it with market expectations post-merger.
When will the reverse stock split take effect?
The reverse stock split is set to occur once the merger closes, with common stock expected to start trading under the new name and ticker symbol soon after.
How will the reverse stock split affect my shares?
Every thirty-five shares you own will be converted into one share of Kintara common stock, while retaining your ownership percentage in the company.
What happens if I own fractional shares?
Kintara will issue enough additional shares to ensure no fractional shares remain, rounding up any resulting fractions to a full share.
Who is involved in managing the reverse stock split?
Equinity Trust Company, LLC will act as the exchange agent handling the logistics of the reverse stock split for shareholders.
